This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Local OB-GYN Practice Helps Study Potential New Treatment For HPV And Cervical Cancer

RICHMOND, Va., Dec. 4, 2012 /PRNewswire/ -- Virginia Women's Center has been selected to participate in a nationwide clinical trial, one that will ultimately hope to prevent the human papillomavirus virus (HPV) from progressing into cervical cancer and treat women who have HPV and the precancerous lesions associated with it. The Richmond-area OB-GYN practice has participated in over 50 clinical research studies since 1997, all of which have contributed to the future of safe and effective medicine for women.

"We feel honored to be able to participate in this study and to play a role in helping further advance medicine for women," said Dr. Peter Zedler, gynecologist and Director of Clinical Research at Virginia Women's Center. "In addition, we feel fortunate that we can offer this potentially life-saving treatment in our local Richmond community."

Gardasil, the first vaccine developed to prevent HPV, was approved by the FDA in 2006 and is now approved for females and males ages nine to 26. Gardasil protects against four strains of the human papillomavirus (HPV).  In females, Gardasil helps protect against the two types of HPV that cause about 75 percent of cervical cancer cases and two additional types that cause 90 percent of genital warts cases. In males, Gardasil helps protect against 90 percent of genital warts cases. Gardasil is ideally given to patients before they become sexually active. Virginia Women's Center was the only research site in the Richmond area involved in the clinical trial leading the approval of Gardasil.

While the Gardasil vaccine has proven to be a safe and effective preventative vaccine, there is still an opportunity to improve treatment for women who have already been exposed to HPV. Dr. Peter Zedler, and his team are currently enrolling participants in a clinical research study to evaluate the effectiveness of a new vaccine that would treat women who have HPV and the precancerous lesions associated with it. The hope is that the vaccine will stimulate the woman's immune system to fight the precancerous lesions and resolve the process, before it progresses to cervical cancer. Currently, for women who have HPV and precancerous lesions, a surgical procedure that removes the tissue is the only option to keep the disease from progressing to cervical cancer. The vaccine may also serve as an alternative to having this surgical procedure.

For more information about this study or to learn more about the other studies that are currently enrolling, please contact a clinical research coordinator at Virginia Women's Center by calling 804.662.6117.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs